- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.03. | Astellas axes early Sjögren's trial in latest setback for autoimmune disease community | ||
| 30.03. | Blackstone closes record $6.3B life sciences fund | ||
| 30.03. | Kevin Tang uses newfound control of Aurinia to finally take over Kezar | ||
| 30.03. | Viridian's other rival to Amgen's Tepezza scores phase 3 win, but investors need convincing | ||
| 30.03. | J&J secures Royalty backing for $500M autoimmune antibody program | ||
| 30.03. | Connect's Dupixent challenger hits the mark in phase 3 eczema trial | ||
| 30.03. | Kardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trial | ||
| 30.03. | Biogen's litifilimab sparkles in midphase lupus trial, raising hopes for pivotal readout | ||
| 30.03. | Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025 | ||
| 27.03. | AstraZeneca's in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset | ||
| 27.03. | Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions | ||
| 27.03. | AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops | ||
| 27.03. | Novartis pens $2B deal for allergy biotech with potential Xolair successor | ||
| 26.03. | OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline | ||
| 26.03. | Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses | ||
| 26.03. | Wave crashes after obesity trial tracks 1% dip in body weight over 6 months | ||
| 26.03. | Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA | ||
| 26.03. | Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus | ||
| 25.03. | After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets | ||
| 25.03. | Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition | ||
| 25.03. | Sarepta's big bet on Arrowhead's siRNA assets yields early data | ||
| 25.03. | Novo Nordisk prepares to go global as triple G prospect passes midphase diabetes test in China | ||
| 25.03. | BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data | ||
| 24.03. | Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors | ||
| 24.03. | Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.